Generic Dymista ( Fluticasone/Azelastine )

Order cheap Generic Dymista (Fluticasone/Azelastine) without dr prescription in the United States

In our USA pharmacy, you can buy Dymista without a prescription, with delivery across the USA within 2‑5 days. Discreet and anonymous packaging.
Dymista is a combination nasal spray containing fluticasone propionate, a corticosteroid, and azelastine hydrochloride, an antihistamine. It is used to treat seasonal allergic rhinitis (hay fever) in patients who require both an intranasal antihistamine and a steroid for symptom relief. Fluticasone reduces inflammation and swelling in the nasal passages, while azelastine blocks histamine to relieve itching, sneezing, and runny nose.
Usual adult dose: One spray (50 mcg fluticasone propionate and 137 mcg azelastine hydrochloride) in each nostril twice daily. A total daily dose delivers 200 mcg fluticasone and 548 mcg azelastine hydrochloride. (Note: the 140 mcg azelastine strength is not the standard U.S. formulation; the FDA‑approved product contains 137 mcg azelastine hydrochloride per spray.)
Dosage form: Nasal spray suspension.
Onset of action: Symptom relief may begin within 30 minutes; full therapeutic benefit typically develops after 1‑2 weeks of continuous use.
Duration of action: Each dose provides approximately 12 hours of symptom control, thus twice‑daily dosing is required for sustained relief.
Alcohol consumption does not directly interact with Dymista, but heavy drinking may worsen nasal congestion and should be moderated during treatment.
Most common side effects: bitter or unpleasant taste, headache, nasal discomfort, and epistaxis (nosebleeds).
Would you like to try Dymista without a prescription?

General Information about Dymista

• INN (International Nonproprietary Name): Fluticasone propionate and azelastine hydrochloride
• Brand names available in the USA: Dymista® (Viatris Specialty LLC, formerly Mylan). No generic equivalent is currently available.
• ATC code: R01AD58 (fluticasone, combinations)
• Dosage forms and strengths: Metered‑dose nasal spray suspension. Each metered spray delivers 137 mcg of azelastine hydrochloride (equivalent to 125 mcg azelastine base) and 50 mcg of fluticasone propionate. The 140 mcg azelastine strength is not marketed in the USA; the U.S. product contains 137 mcg per spray.
• Manufacturers in USA: Viatris Specialty LLC (brand Dymista®); the product is manufactured for Viatris by various contract facilities. No generic manufacturers currently produce this combination.
• Registration status in USA: Approved by the U.S. Food and Drug Administration (FDA) on August 26, 2011 (NDA 022236).
• OTC / Rx classification: Prescription only (Rx).

Mechanism of Action and Pharmacology

Dymista combines two active agents with complementary mechanisms. Azelastine is a potent, selective histamine H1‑receptor antagonist with mast‑cell‑stabilizing and anti‑inflammatory properties. It inhibits the release of histamine, leukotrienes, and other mediators from mast cells and other inflammatory cells, providing rapid relief of itching, sneezing, and rhinorrhea. Fluticasone propionate is a synthetic corticosteroid with high glucocorticoid receptor affinity that reduces the transcription of pro‑inflammatory cytokines, chemokines, and adhesion molecules. It decreases nasal mucosal inflammation, edema, and hyper‑reactivity, addressing the underlying allergic inflammation. The combination targets both the early‑phase (histamine‑mediated) and late‑phase (inflammatory) allergic responses. Following intranasal administration, systemic absorption of both components is minimal; fluticasone propionate undergoes extensive first‑pass metabolism, and azelastine is metabolized primarily by CYP3A4. Peak plasma concentrations of azelastine occur approximately 2‑3 hours after dosing, while fluticasone absorption is negligible. The terminal half‑life of azelastine is about 22 hours, but the local pharmacodynamic effect lasts approximately 12 hours, warranting twice‑daily dosing.

Indications

• Symptomatic treatment of seasonal allergic rhinitis in adults and pediatric patients 6 years of age and older who require treatment with both an intranasal antihistamine and an intranasal corticosteroid.
• May also be used for perennial allergic rhinitis in patients who have not responded adequately to monotherapy with either component.

Important Warnings and Precautions

Dymista is for intranasal use only. Avoid spraying into the eyes or mouth. It may cause epistaxis and nasal ulceration; periodic nasal examination is recommended, especially with long‑term use. The fluticasone component can suppress the hypothalamic‑pituitary‑adrenal (HPA) axis; monitor for signs of adrenal insufficiency, particularly in patients transferred from systemic steroids or those receiving high doses for prolonged periods. Growth retardation may occur in children with extended use of corticosteroids; pediatric patients should be monitored. The azelastine component may cause somnolence in some patients; caution is advised when driving or operating machinery. Concomitant use of alcohol or other central nervous system depressants may enhance sedation. Use with caution in patients with a history of increased intraocular pressure, glaucoma, or cataracts. Immunosuppression from corticosteroids may increase susceptibility to infections; avoid exposure to chickenpox or measles. Dymista is not recommended for the treatment of nasal symptoms associated with infection. The combination product is contraindicated in patients who are hypersensitive to any of its ingredients.

At‑risk groups

• Elderly: No dose adjustment is necessary; however, elderly patients may be more sensitive to the effects of corticosteroids and antihistamines. Monitor for increased intraocular pressure and nasal ulceration.
• Pregnancy: There are no adequate, well‑controlled studies in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Fluticasone propionate is pregnancy Category C; azelastine hydrochloride is Category C. Animal studies have shown adverse fetal effects at high doses.
• Breastfeeding: It is not known whether fluticasone propionate or azelastine are excreted in human milk following intranasal administration. Because many drugs are excreted in human milk, caution should be exercised when Dymista is administered to a nursing mother.
• Renal impairment: No dose adjustment is required; systemic absorption is negligible.
• Hepatic impairment: Fluticasone propionate undergoes extensive first‑pass hepatic metabolism; patients with severe hepatic impairment may have increased systemic exposure. Use with caution; no specific dose adjustment is recommended.
• Pediatric: Safety and efficacy have been established for patients 6 years and older. The recommended dose is the same as for adults. Safety and efficacy in children under 6 years have not been established.
• Immunocompromised patients: Caution is advised; corticosteroids may increase the risk of infections.

Driving and alcohol

Azelastine, a component of Dymista, may cause drowsiness in some individuals. Patients should avoid driving or operating heavy machinery until they know how the medication affects them. Alcohol and other central nervous system depressants may enhance this sedative effect; alcohol consumption should be limited during treatment.

Dosage Instructions

• Adults and pediatric patients 12 years and older: One spray (50 mcg fluticasone propionate / 137 mcg azelastine hydrochloride) in each nostril twice daily.
• Pediatric patients 6 to 11 years: One spray (50 mcg fluticasone propionate / 137 mcg azelastine hydrochloride) in each nostril twice daily. Safety and effectiveness have not been established in patients under 6 years.
• Administration: Shake the bottle gently before each use. Prime the pump by spraying into the air (away from the face) until a fine mist appears before the first use or if the spray has not been used for 14 days or more. Gently blow your nose to clear nostrils. Insert the tip into one nostril, close the other nostril, and spray while breathing in gently. Repeat in the other nostril. Wipe the tip with a clean tissue and replace the cap.
• Missed dose: If a dose is missed, skip the missed dose and resume the regular schedule. Do not double the dose.

Side Effects and Contraindications

Most common adverse reactions (incidence ≥2% and more than placebo): Dysgeusia (bitter or unpleasant taste, 6‑8%), headache (6‑7%), epistaxis (nosebleed, 5‑6%), nasal discomfort (3‑4%), and sneezing (2‑3%). These effects are generally mild and transient.
Other adverse reactions: Somnolence, cough, dry mouth, nausea, and fatigue have been reported. Nasal ulceration and septal perforation are rare but possible with prolonged corticosteroid use. Hypersensitivity reactions including urticaria, angioedema, and bronchospasm can occur.
Serious adverse reactions: Adrenal suppression with prolonged high‑dose use; growth retardation in children; increased intraocular pressure and glaucoma; cataract formation; and severe allergic reaction. Discontinue if any of these develop.
Absolute contraindications: Known hypersensitivity to fluticasone propionate, azelastine hydrochloride, or any excipient.

Drug Interactions

• CNS depressants (alcohol, sedatives, tranquilizers): Additive sedative effects with azelastine; limit alcohol and use other depressants with caution.
• CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, clarithromycin): Azelastine is metabolized by CYP3A4; concomitant use may increase systemic exposure, but clinically relevant interactions are unlikely at recommended intranasal doses. No dose adjustment is required.
• Other intranasal corticosteroids: Concurrent use may increase the risk of local adverse effects like epistaxis and nasal ulceration; avoid if possible.
• Vaccines: Live virus vaccines should not be given to patients on immunosuppressive doses of corticosteroids. Intranasal fluticasone is not considered immunosuppressive at therapeutic doses, but caution is advised.
• No clinically significant pharmacokinetic interactions have been observed with other commonly prescribed medications.

Practical Advice

• Use Dymista exactly as prescribed, one spray in each nostril twice daily. Do not exceed the recommended dose.
• Prime the spray pump before initial use and after any storage period of 14 days or longer to ensure the correct dose is delivered.
• Avoid spraying into the eyes or mouth. If accidental contact occurs, rinse thoroughly with water.
• Gently blow your nose before administration. Do not tilt your head backward; keep it upright or slightly forward.
• If you miss a dose, skip it and take the next dose at the regular time. Do not double the dose.
• The bitter taste is common but harmless; drinking a small amount of water or juice after spraying may help.
• Store upright at room temperature (20‑25°C / 68‑77°F) with the cap closed. Do not freeze. Keep out of reach of children.
• Discard the bottle after 120 sprays have been used, or by the expiration date, whichever comes first.
• Inform your healthcare provider if you develop persistent nosebleeds, nasal pain, or changes in vision.
• Do not share your nasal spray with others, as this may spread infection.

Alternative Medications

• Fluticasone propionate alone (Flonase® Sensimist, generic): Intranasal corticosteroid for allergic rhinitis; may be sufficient for patients who do not require an antihistamine component. Available OTC.
• Azelastine hydrochloride alone (Astelin®, Astepro®): Intranasal antihistamine; provides rapid symptom relief. Available OTC as Astepro.
• Olopatadine hydrochloride nasal spray (Patanase®): Another intranasal antihistamine for seasonal rhinitis, dosed twice daily.
• Combination of separate intranasal steroid and oral antihistamine: Some patients may use fluticasone nasal spray plus an oral antihistamine (cetirizine, loratadine, fexofenadine) to achieve similar dual control.

Clinical Efficacy

The clinical efficacy of Dymista was evaluated in several randomized, double‑blind, placebo‑controlled trials in patients with seasonal allergic rhinitis. In a pivotal 14‑day study, Dymista administered as one spray per nostril twice daily significantly reduced the total nasal symptom score (TNSS) compared with placebo, fluticasone propionate alone, and azelastine alone. The combination achieved an onset of symptom relief within 30 minutes and provided a statistically significant and clinically meaningful improvement over monotherapy. The mean reduction in TNSS from baseline was approximately 4‑5 points greater than placebo. The combination was well tolerated, with the most common adverse event being dysgeusia. Subsequent studies confirmed that Dymista is superior to either component alone in controlling nasal and ocular symptoms, supporting its use in patients with moderate‑to‑severe allergic rhinitis not adequately managed by monotherapy.

Important:

Dymista (fluticasone propionate/azelastine hydrochloride nasal spray) is a prescription combination medication for the treatment of seasonal allergic rhinitis. It must be used exactly as directed by a healthcare provider. This product is for intranasal use only. Do not spray in the eyes or mouth. It may cause drowsiness; avoid driving or operating machinery until you know how the medication affects you. Alcohol should be limited during treatment. Long‑term use may cause nasal irritation or ulceration; periodic nasal examinations are recommended. Pediatric growth should be monitored with prolonged corticosteroid use. If you become pregnant or are breastfeeding, consult your doctor before use. Keep out of reach of children. The information provided is not a substitute for professional medical advice.

How to buy Generic Dymista no prescription U.S. Online Pharmacy